INT24886

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.12
First Reported 1989
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 11
Total Number 11
Disease Relevance 4.35
Pain Relevance 5.03

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (SFTPA1) extracellular region (SFTPA1)
Anatomy Link Frequency
globus pallidus 2
tears 1
brain 1
SFTPA1 (Homo sapiens)
Pain Link Frequency Relevance Heat
substance P 102 100.00 Very High Very High Very High
antagonist 37 100.00 Very High Very High Very High
Enkephalin 14 100.00 Very High Very High Very High
aspirin 18 99.76 Very High Very High Very High
Inflammation 96 99.60 Very High Very High Very High
Infliximab 42 97.72 Very High Very High Very High
Arthritis 95 96.92 Very High Very High Very High
Inflammatory mediators 29 95.20 Very High Very High Very High
Pain 13 94.92 High High
calcitonin gene related peptide 32 93.32 High High
Disease Link Frequency Relevance Heat
Striatonigral Degeneration 6 99.80 Very High Very High Very High
INFLAMMATION 117 99.60 Very High Very High Very High
Hypersensitivity 38 99.48 Very High Very High Very High
Disease 78 99.06 Very High Very High Very High
Arthritis 31 96.92 Very High Very High Very High
Gastroesophageal Reflux Disease 24 96.16 Very High Very High Very High
Pain 14 94.92 High High
Esophageal Disease 44 92.08 High High
Disorders Of The Lacrimal System 3 89.44 High High
Acquired Immune Deficiency Syndrome Or Hiv Infection 141 87.28 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In the cases with Huntington's disease (HD) and striatonigral degeneration (SND), marked loss of calcineurin, MEnk and SP-like immunoreactivities was seen in the globus pallidus corresponding to areas of striatal neurodegeneration, whereas synaptophysin immunoreactivity remained in areas which revealed almost complete loss of calcineurin, MEnk and SP-like immunoreactivities.
Negative_regulation (loss) of SP in globus pallidus associated with striatonigral degeneration, enkephalin, disease and substance p
1) Confidence 0.12 Published 1989 Journal Acta Neuropathol. Section Abstract Doc Link 2479214 Disease Relevance 0.45 Pain Relevance 0.88
In this study we also show that SP, CGRP, and VIP are normally present in tears of allergic subjects and increase after conjunctival allergen challenge.
Negative_regulation (present) of SP in tears associated with hypersensitivity and substance p
2) Confidence 0.11 Published 2011 Journal Molecular Vision Section Body Doc Link PMC3021574 Disease Relevance 0.72 Pain Relevance 0.39
In the cases with Huntington's disease (HD) and striatonigral degeneration (SND), marked loss of calcineurin, MEnk and SP-like immunoreactivities was seen in the globus pallidus corresponding to areas of striatal neurodegeneration, whereas synaptophysin immunoreactivity remained in areas which revealed almost complete loss of calcineurin, MEnk and SP-like immunoreactivities.
Negative_regulation (loss) of SP in globus pallidus associated with striatonigral degeneration, enkephalin, disease and substance p
3) Confidence 0.09 Published 1989 Journal Acta Neuropathol. Section Abstract Doc Link 2479214 Disease Relevance 0.47 Pain Relevance 0.90
Since cellular immune infiltrate is a prerequisite for severe inflammation and tissue damage, inhibition of IL-8, SP and PAF-induced PBL migration and activation may provide potential targets for therapy.


Negative_regulation (inhibition) of SP associated with inflammation and substance p
4) Confidence 0.05 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978390 Disease Relevance 0.58 Pain Relevance 0.65
This parallels the success of TNF inhibition in adult SpA (Mease et al 2000; Van Den Bosch et al 2002; Brandt et al 2003; Davis et al 2003; Calin et al 2004; Antoni et al 2005a, 2005b; Marzo-Ortega et al 2005; Mease et al 2005; van der Heijde et al 2005, 2006a, 2006b; Genovese et al 2007).
Negative_regulation (inhibition) of SpA
5) Confidence 0.05 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721362 Disease Relevance 0.58 Pain Relevance 0.50
In contrast, a PAF antagonist and a neurokinin-1 receptor antagonist (ie, SP antagonist) significantly reduce supernatant-induced H2O2 production.
Negative_regulation (antagonist) of SP associated with antagonist and substance p
6) Confidence 0.05 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978390 Disease Relevance 0.33 Pain Relevance 0.73
Evaluation of the construct validity of the OHIP-Sp
Negative_regulation (Evaluation) of OHIP-Sp
7) Confidence 0.02 Published 2006 Journal BMC Oral Health Section Body Doc Link PMC1534011 Disease Relevance 0.19 Pain Relevance 0.19
Evaluation of the construct validity of the OHIP-Sp
Negative_regulation (Evaluation) of OHIP-Sp
8) Confidence 0.02 Published 2006 Journal BMC Oral Health Section Body Doc Link PMC1534011 Disease Relevance 0.19 Pain Relevance 0
In the presence of Sp4 in the brain, one could speculate that this effect may be magnified, because Sp4 binding to sites I and II is not affected by the loss of Sp binding to site III, and the resulting stimulated LTR may have high levels of both Sp and NF-?
Negative_regulation (loss) of Sp in brain
9) Confidence 0.02 Published 2009 Journal Retrovirology Section Body Doc Link PMC2805609 Disease Relevance 0.58 Pain Relevance 0
Both aspirin-mediated permeability and phosphorylation of p38 MAPK were significantly attenuated by SB-203580 (a p38 MAPK inhibitor) but not by U-0126 (a MEK1 inhibitor) or SP-600125 (a JNK inhibitor).
Negative_regulation (inhibitor) of SP-600125 associated with aspirin
10) Confidence 0.01 Published 2008 Journal Am. J. Physiol., Cell Physiol. Section Abstract Doc Link 18667601 Disease Relevance 0.13 Pain Relevance 0.40
Both aspirin-mediated permeability and phosphorylation of p38 MAPK were significantly attenuated by SB-203580 (a p38 MAPK inhibitor) but not by U-0126 (a MEK1 inhibitor) or SP-600125 (a JNK inhibitor).
Negative_regulation (inhibitor) of SP-600125 associated with aspirin
11) Confidence 0.01 Published 2008 Journal Am. J. Physiol., Cell Physiol. Section Abstract Doc Link 18667601 Disease Relevance 0.13 Pain Relevance 0.40

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox